PreciseDx
Business Services · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1111 Amsterdam Stuyvesant Bldg 8-822, Ne...Phone Number
(646) 818-9330Website
www.precisedx.aiRevenue
$6.1 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About PreciseDx
PreciseDx is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, enabling better and more personalized treatment and outcomes.Explore more
PreciseDx Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is PreciseDx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if PreciseDx had a recent Job posting/layoffs
Product Launch: Get notified when PreciseDx launches new products
PreciseDx, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if PreciseDx is spiking on competitors!
Earning: See what the market has to say on PreciseDx recently announced quarterly report
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once PreciseDx has new funding data
Congratulate Masked Content for being promoted to Masked Content at PreciseDx
Check if PreciseDx has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined PreciseDx as Masked Content
Find more new buyers
Compare Similar Companies to PreciseDx
Compare insights from companies similar to PreciseDx, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
PreciseDx is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
PreciseDx is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about PreciseDx.
PreciseDx financials insights
Gather financial insights about PreciseDx, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$10.8M
2024
Series B
$20.7M
2025
Other Financing Round
$11M
PreciseDx Tech Stack
A closer look at the technologies used by PreciseDx
Most Recent Scoops
Funding
Funding
Funding
Funding
Lateral Move
Executive Move
Edward Diehl, Vice President of Commercial Oncology, has transitioned to the role of Vice President, Commercial Development.
Award
New Hire
Executive Move
PreciseDx News & Media
PreciseDx Continues Path to Commercial Launch: Secures Additional Funding and Announces New Leadership
Funding now totals over $43 million, strengthened leadership focused on a 2026 commercial launch of the OncoIntelligence™-driven, PreciseBreast™ NEW YORK, June 18, 2025 /PRNewswire/ -- PreciseDx, the leading innovator behind PreciseBreast, a novel breast cancer diagnostic that is powered...Study Results from COTA, PreciseDx, and Baptist Health South Florida Confirm Novel AI Test, PreciseBreast is Equivalent to Oncotype DX at Predicting Breast Cancer Recurrence
Findings to be Presented at the San Antonio Breast Cancer Symposium NEW YORK, Dec. 9, 2024 /PRNewswire/ -- COTA Inc., a leader in real-world data (RWD) and analytics for oncology, PreciseDx, an innovator in AI-powered digital pathology focused on oncology diagnostics, and Baptist Health...PreciseDx Announces Formation of Scientific Advisory Board
World-Renowned Breast Cancer Oncology and Pathology Experts to Advise Company on the Advancement of its AI-Powered PreciseBreastTM Risk of Recurrence Assessment and Product Portfolio NEW YORK, Nov. 20, 2024 /PRNewswire/ -- PreciseDx, a leading innovator in AI-powered digital pathology...PreciseDx Secures $20.7 Million Series B to Advance AI-Powered Cancer Risk Assessments
Funding will Support Expanded Commercialization Efforts for PreciseBreast Risk Assessment PreciseDx, a leading innovator in oncology diagnostics leveraging Artificial Intelligence (AI) for new, morphology-driven disease analysis, today announced that it has raised $20.7 million in Series B funding, bringing its total funding to date to $31.5 million. The round was led by Eventide Asset Management
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding PreciseDx
Sign Up For FreeTo access detailed company insights
PreciseDx is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, enabling better and more personalized treatment and outcomes.... Read More
